Sonoma pharmaceuticals and emc pharma announce an exclusive partnership to expand commercial channels of the microcyn®-based rx dermatology and eye care products nationwide

Woodstock, ga.--(business wire)--sonoma pharmaceuticals, inc. (nasdaq: snoa), a global healthcare leader developing and producing stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has entered into an agreement with emc pharma, llc for the exclusive right to manage, market and distribute sonoma's hocl-based prescription dermatology and eye care products in the united sta
SNOA Ratings Summary
SNOA Quant Ranking